AbbVie Loses Judge-Switch Bid in Humira Fraud Case
As reported by law360, AbbVie Inc.’ motion to have a single judge rule over a pair of fraud cases in which the pharmaceutical company allegedly illegally marketed its drug Humira has been denied
AbbVie Agrees to $24 Million Settlement with California Department of Insurance and Whistleblower Over Humira Marketing Fraud
Lawsuit alleged AbbVie pharmaceutical company committed fraud in promotion of blockbuster prescription drug Humira The California Department of Insurance has announced a settlement agreement with AbbVie Inc. to resolve a lawsuit alleging the pharmaceutical giant violated the California Insurance Frauds Prevention Act (Act) by providing kickbacks to healthcare providers throughout California relating to the sale of its
AbbVie Medical Fraud Lawsuit Highlights Growing Nationwide Concern With Big Pharma Paying Doctors to Get New Customers
As reported by USA Today, there is a growing concern across the U.S. over the apparent surge in dangerous and highly expensive medications being pushed on the public by drug manufactures whose main concern is not turning a new corner in patient health but rather turning over millions in profits.
Plaintiffs Get AbbVie Medical Fraud Case Remanded to State Court
On September 18, 2018, Lieff Cabraser and California Insurance Commissioner Dave Jones sued AbbVie, Inc. for violations of the Insurance Frauds Prevention Act (“IFPA”) by providing kickbacks to healthcare providers throughout California relating to sale of the immunosuppressive drug Humira. Defendant AbbVie removed the case to federal court, arguing that the State of California should
California Department of Insurance Intervenes in Lieff Cabraser’s Lawsuit Against AbbVie Alleging Kickbacks and Improper Marketing of Top-Selling Drug Humira
Joint Complaint Filed Under the California Insurance Frauds Prevention Act On September 18, 2018, Lieff Cabraser and California Insurance Commissioner Dave Jones sued AbbVie, Inc. for violations of the Insurance Frauds Prevention Act (“IFPA”) by providing kickbacks to healthcare providers throughout California relating to sale of the immunosuppressive drug Humira. Humira, used to treat arthritis,